Definium Therapeutics, Inc.
DFTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Definium Therapeutics, Inc. focuses on Biotechnology services and products. Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. With a market capitalization of $5.88B, it sits in mid-cap territory. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Market Cap
$5.88B
Beta
2.21
P/E (TTM)
—
P/E (Fwd)
-29.31
EPS (TTM)
$-2.51
EPS (Fwd)
$-1.51
ROE
-94.7%
ROA
-35.7%
Cash
$373.4M
Total Debt
$40.8M
Free CF
-$45.6M
52W Change
398.8%
Annual Financials
Cash vs Debt
With $373.4M in cash and $40.8M in debt, DFTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$45.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -94.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Definium Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Definium Therapeutics, Inc. and its sector.